Online inquiry

IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7963MR)

This product GTTS-WQ7963MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL7R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002185.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3575
UniProt ID P16871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7963MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4797MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ13416MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ9307MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ7969MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-17
GTTS-WQ11689MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ10579MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ4733MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ4139MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW